阿斯利康.pptVIP

创新，全球化的动力 创新 – 全球化的动力Innovation – the Driving Force behind Globalization 制药行业 The Pharma industry 制药行业的创新 Innovation in the pharma-industry 什么是全球化？ What is globalization? 国际企业中的领导力 Leadership in a global company 中国的制药行业 Pharma market in China Q A 创新和全球化Innovation and Globalization 创新和全球化是相互依存、相互促进的 Innovation and globalization are mutually dependent and enabling 只有不断创新的企业才能在全球获得成功 Only innovative companies can successfully globalize 全球化的企业更能支付和回收越来越高的创新成本 Global companies are more able to afford and recover the higher and higher cost of innovation 我们的目标Our Ambition 一个富于创新的、快速的和高效的公司，凭借其全球范围内的销售和市场方面的优势，充分挖掘并实现研发的巨大潜力，从而提供持续的、顶尖的财政增长。 A creative, fast and effective company with the global sales and marketing strength to realize the full potential from productive RD – thereby delivering sustainable top tier financial growth. Sir Tom McKillop CEO AstraZeneca October 2003 阿斯利康工作重点AZ’ s Key Business Priorities 制药行业的结构 - 2002Pharma Industry Structure - 2002 阿斯利康2002年关键的统计数据AstraZeneca 2002 Key Statistics 178亿的销售额 Sales of 17.8 billion 营运利润44亿美元 Operating profit of $4.4 billion 全球58000员工 58,000 employees worldwide 研发费用超过30亿 – 销售额的17% RD spend of more than 3 billion – 17% of sales 10 – 12 years to bring new medicine to market 在5个国家拥有9个大型研发中心 9 major RD centers in 5 countries 在20个国家拥有34个生产基地 34 manufacturing facilities in 20 countries 顶级的销售队伍和广泛的分布：在美国超过6000名；美国之外超过14000名 Top echelon sales force size and reach; 6,000 US reps; 14,000 outside US 到2006年全球制药市场的增长 – 美国是主要的增长点Global Growth to 2006 – Driven by the US 对21世纪制药行业的新建议New Suggestions for the Pharma Industry in the 21st Century 在各方面，从研发到销售，美国占主导地位 USA dominant on all dimensions from discovery to sales 拉丁美洲受到来自亚洲的挑战 Latin America challenged by Asia 创新产品的减少和市场跟随者竞争力的加强，给传统研发活动带来的挑战增加 Less productive pipelines and more rapid catch-up challenging the historic RD paradigm 少数大型企业占主导地位 Major players dominate key franchises 中国 – 远大的发展前景China – the Great Future Potential 制药行业面临的主要挑战Major Chal